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Although aberrant metabolism in tumors has been
well described, the identification of cancer subsets
with particular metabolic vulnerabilities has re-
mained challenging. Here, we conducted an siRNA
screen focusing on enzymes involved in the tricar-
boxylic acid (TCA) cycle and uncovered a striking
range of cancer cell dependencies on OGDH, the
E1 subunit of the alpha-ketoglutarate dehydroge-
nase complex. Using an integrative metabolomics
approach, we identified differential aspartate utiliza-
tion, via the malate-aspartate shuttle, as a predictor
of whether OGDH is required for proliferation in 3D
culture assays and for the growth of xenograft
tumors. These findings highlight an anaplerotic role
of aspartate and, more broadly, suggest that differ-
ential nutrient utilization patterns can identify sub-
sets of cancers with distinct metabolic depen-
dencies for potential pharmacological intervention.INTRODUCTION
The genetic changes underlying aberrant cancer cell prolifera-
tion signal a rewiring of metabolism to balance macromolecular
biosynthesis with ATP production (Ward and Thompson, 2012).
Since metabolic reprogramming has gained acceptance as a
hallmark of most cancers (Hanahan and Weinberg, 2011), the
development of therapeutic strategies to target key metabolic
dependencies has attracted much attention. While the clinical
feasibility of targeting metabolism has long been established
by multiple approved agents targeting nucleic acid metabolism
(Vander Heiden, 2011), a goal for the next wave of novel thera-
peutic agents targeting deregulated tumor metabolism will be
to use the personalized medicine paradigm to identify more se-
lective agents that can be utilized in defined cancer subtypes.
Large-scale cancer sequencingefforts have identified relatively
few recurrent mutations in metabolic genes and fewer still with
clear gain-of-function roles. The notable exceptions are IDH1
and IDH2, where mutations lead to a novel enzymatic activity876 Cell Reports 17, 876–890, October 11, 2016 ª 2016 The Author(s
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2009). In fact, the first inhibitors of mutant IDH1 and IDH2 have
demonstrated promising signs of efficacy in early clinical trials
(Stein and Tallman, 2016). Since other mutations in metabolic
genes, across diverse tumor types, are associated with a loss
of function, synthetic lethal approaches have been undertaken
to identify specific dependencies in these contexts, such as
enolase 2 in ENO1-deleted tumors (Muller et al., 2012) and
heme oxygenase in FH-null tumors (Frezza et al., 2011). Alterna-
tively, exploiting cancer-specific auxotrophies has shown prom-
ise, suchasdependenceonarginine in thecontextof ASS1-nega-
tive tumors (Qiu et al., 2014). The general approach of identifying
nodes of particular metabolic sensitivity has been expanded to
more common cancer genotypes, such as PRPS2 in Myc-driven
tumors (Cunningham et al., 2014) and glutaminase in VHL-null
renal tumors (Gameiro et al., 2013). Recent studies have also
pointed to enhanced dependency on glutaminase in mesen-
chymal-type tumor cells (Ulanet et al., 2014), and inhibitors target-
ing glutaminase are currently being tested in clinical trials (Gross
et al., 2014).
While the success of therapeutic strategies targeting nutrient
utilization pathways remains to be determined, the complex
in vivo microenvironment and metabolic plasticity of tumors
may prevent sufficient crippling of tumors by blocking a single-
nutrient utilization pathway. For instance, although glutamine is
recognized as an important anaplerotic source in cancer cells
in vitro, glucose oxidation via pyruvate carboxylase may pre-
dominate in the in vivo tumor setting (Davidson et al., 2016;
Sellers et al., 2015). A lack of glutamine oxidation in the tricar-
boxylic acid (TCA) cycle was reported for brain tumors, which
were demonstrated to simultaneously oxidize glucose and ace-
tate (Mashimo et al., 2014). Internalization of extracellular protein
via macropinocytosis was identified as a feature of Ras-trans-
formed cells, resulting in yet another way to acquire glutamine
and other amino acids (Commisso et al., 2013).
Due to themultitude of potential nutrient sources and routes of
feeding carbon into the TCA cycle, we investigated whether
directly targeting TCA cycle enzymes could serve as a more
definitive means of blocking this pathway. In an small interfering
RNA (siRNA) screen, we identified OGDH, the E1 subunit of
alpha-ketoglutarate dehydrogenase complex (OGDHC), as the
top hit. OGDH catalyzes the conversion of a-ketoglutarate).
creativecommons.org/licenses/by-nc-nd/4.0/).
(aKG) to succinyl-CoA and significantly contributes to mitochon-
drial NADH production (Mullen et al., 2014). While OGDH has
been reported to contribute to fumarate accumulation and
optimal growth of FH-deficient cells (Sullivan et al., 2013), we
wanted to determine its role in a broader array of cancer cell
lines. A recent report demonstrated differential sensitivity of
several cell lines to the phosphonate analog of alpha-ketogluta-
rate andOGDH inhibitor, succinyl phosphonate (SP) (Bunik et al.,
2016). We used highly validated small hairpin RNA (shRNA) tools
in an expanded panel of cancer cell lines and identified a range of
cellular dependence on OGDH, with some cell lines being
completely OGDH independent. The reliance on OGDH was
context dependent and in a more stringent, modified version of
a 3D culture assay (m3D), only a small subset of lines was sensi-
tive to OGDH knockdown. Notably, significantly impaired growth
upon OGDH knockdown in m3D translated to a striking depen-
dence on OGDH for tumor growth in vivo and was associated
with a distinct pattern of aspartate carbon and nitrogen utiliza-
tion. These findings lend support for further investigation of
OGDH as a therapeutic target in a metabolically distinct subset
of cancers.
RESULTS
siRNA Screen Focused on TCA Cycle Components
Highlights OGDH
To functionally understand TCA cycle and identify steps
particularly critical for cell viability, we undertook a focused
siRNA-based screen of TCA cycle genes in A549 cells, a
model cancer cell line with fast growth kinetics in vitro
and in vivo (Figure 1A). For completeness, we included addi-
tional genes encoding homologs performing similar enzymatic
functions, but localized to the cytosol. To ensure that we
thoroughly assess the contribution of each gene to the cell
proliferation, we implemented a multi-transfection protocol
designed to start the growth assay with the cells already under
conditions of significant target gene knockdown (Figure S1A).
Using a very abundant target, GAPDH, as a control, we
showed that significant knockdown is maintained for the entire
duration of the assay (Figure S1B).
Using this multi-transfection procedure, we successfully
achieved knockdown of all genes analyzed, as measured by
qPCR at the beginning of the assay and the amount of residual
mRNA was, on average, 3.5% (Figure S1C). Surprisingly, a
wide spectrum of growth defects was observed, ranging from
none to severe (Figure 1B). The strongest hit was OGDH, the
E1 subunit of alpha-ketoglutarate dehydrogenase complex. To
further validate this hit, we deconvoluted the initial OGDH siRNA
pool by repeating the knockdown experiment with individual
siRNA duplexes. Similar findings were observed with multiple
duplexes, suggesting that the results are likely to be on target
(Figure S1D). To increase confidence in our findings, we devel-
oped multiple doxycycline (dox)-inducible shRNAs capable of
knocking down OGDH: sh815, sh885, sh1137 (Figure 1C), which
resulted in profound dox-dependent growth defects in a colony
formation assay (Figure 1D).
To conclusively show that the effects observedwere on target,
we conducted rescue experiments with wild-type OGDH thatwas engineered to be resistant to multiple shRNAs. To formally
demonstrate that an enzymatic activity, rather than any potential
scaffolding role, is critical for the growth of cells, we designed a
catalytically dead version of OGDH. Since an X-ray structure of
humanOGDHwas not available, a homologymodel was built us-
ing the crystal structure ofMycobacterium smegmatis alpha-ke-
toglutarate decarboxylase homodimer, and two corresponding
human mutants were predicted to be catalytically dead, R509K
and H513F. Indeed, overexpression of wild-type OGDH, but
not either of the catalytically dead versions, led to a consistent
rescue of growth phenotypes of all three shRNAs (Figures 1E
and 1F; data not shown). Collectively, this establishes a high
degree of confidence in the genetic tools used for all the subse-
quent studies and validates OGDH as a point of particular sensi-
tivity in A549 cells.
OGDH Is Necessary for TCA Cycle Metabolism In Vitro
and In Vivo
To investigate the metabolic consequences of OGDH knock-
down, we conducted multiple analyses that take advantage of
the inducible shRNA system, allowing investigation of how
OGDH knockdown affects cells, but before any overt loss of
cell viability. First, we measured steady-state pool levels of
TCA cycle intermediates and observed significant decreases in
malate abundance with concomitant increases in aKG levels
(Figure 2A). These changes were consistent with the metabolites
being downstream and upstream of OGDH, respectively. As
expected, aspartate levels also significantly decreased (Fig-
ure 2A), since aspartate is rapidly synthesized by cancer cells
from oxaloacetate via aminotransferase activity and has been
used as a proxy measure of TCA cycle activity (DeBerardinis
et al., 2007). Interestingly, total citrate levels were only slightly
decreased and total glutamate levels were unaffected by
OGDH knockdown (Figure S2A). Second, we used a well-estab-
lished in vitro anaplerotic substrate, 13C5-glutamine, to trace
carbon flow in the TCA cycle in cells withOGDH knockdown (Fig-
ures 2B and S2B). These data show a clear constriction in the
TCA cycle at the OGDH step. Significant decreases in the abun-
dance of 13C4 isotopomers of malate, aspartate, and citrate were
observed (Figures 2B and S2B). Increases in the abundance of
13C5 isotopomers of aKG and citrate were also observed, con-
sistent with lower alpha-ketoglutarate dehydrogenase enzyme
activity. To further characterize these metabolic phenotypes,
we conducted time course labeling experiments using 13C5-
glutamine and 13C6-glucose showing that both glucose and
glutamine contribute carbon to the TCA, and effects of OGDH
knockdown can be monitored with both labeling strategies (Fig-
ure S2C). Consistent with the previous results, OGDH appears
to affect glucose entry into the TCA, as the abundance of 13C2-
citrate isotopomer was dramatically decreased upon OGDH
knockdown in a 13C6-glucose-labeling experiment. Collectively,
these data suggest a functional E1 (OGDH) component of the
alpha-ketoglutarate dehydrogenase complex is necessary for
normal oxidative TCA cycle function.
To investigate whether OGDH was required for tumor mainte-
nance in vivo, we conducted a xenograft study where doxycy-
cline was added to animals harboring already established tu-
mors of approximately 200 mm3. OGDH knockdown mediatedCell Reports 17, 876–890, October 11, 2016 877
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Figure 1. siRNA Screen of TCA Cycle Genes Highlights the Key Role of OGDH
(A) Schematic illustrating the TCA cycle. All the genes included in the screen are shown in blue, and homologs localized to the cytosol are denoted in italics.
(B) siRNA screen in A549 cells. Relative growth defects after knockdown of individual genes are normalized to the average of several experiments where cells
were transfected with NT control siRNA pool.
(C) Immunoblot analysis showing effective OGDH knockdown using shRNAs after 4 days of dox treatment.
(D) Dox-dependent OGDH knockdown leads to growth defects in a colony formation assay.
(E) Immunoblot analysis showing overexpression of shRNA-resistant OGDH, wild-type, and R509K mutant in shRNA knockdown lines (shNT and sh885).
(F) Rescue of sh885-induced cell growth phenotypes by wild-type OGDH but not the R509K mutant.by doxycycline-inducible sh885 resulted in significant growth
defects (Figure 2C). The effect was rescued by overexpression
of an shRNA-resistant wild-type OGDH, but not the catalytically
dead R509K mutant OGDH. Similar to in vitro studies, OGDH
protein was efficiently knocked down in vivo (Figure 2D), which
resulted in a significant decrease of enzymatic activity in tumor
lysates at the end of the study (Figure 2E). Metabolic evaluation
of tumors revealed similar TCA cycle perturbations in vivo as
compared to in vitro experiments (Figure 2F). Collectively, these
data suggest that OGDH, and thus the alpha-ketoglutarate dehy-
drogenase complex, contributes to TCA cyclemetabolism and is
necessary for growth of A549 cells in vitro and in vivo.878 Cell Reports 17, 876–890, October 11, 2016Cells Display a Broad Range of Sensitivities to OGDH
Knockdown
To define cancer subtypes particularly susceptible to reduction
of OGDH function, we opted for an expanded shRNA-based
screen using the two highly validated shRNAs targeting OGDH
(sh815 and sh885) and an additional control, shNT. Conse-
quences of OGDH knockdown on cell proliferation were as-
sessed using several different assays. The standard assay con-
sisting of plating cells on 2D plastic plates under low-density
conditions was used. While easy to conduct, this assay does
not recapitulate many aspects of tumor cells in vivo and conse-
quently has relatively limitedpredictive power of in vitro-to-in vivo
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Figure 2. OGDH Is Necessary for TCA Cycle Metabolism In Vitro and In Vivo
(A) OGDH knockdown affects steady-state pool size of multiple metabolites in vitro.
(B) OGDH knockdown affects 13C5-glutamine labeling patterns in vitro.
(C) Xenograft growth of A549 cells expressing sh885 with several versions of the overexpression vector: empty control, OGDH wild-type rescue, OGDH R509K
catalytically dead mutant. Error bars represent SEM. Percentage of tumor growth inhibition (TGI) is indicated on each of the panels, along with the corresponding
p value.
(D) Immunoblot analysis showing effective OGDH knockdown at the end of the in vivo efficacy study. Five individual tumor samples from each cohort are shown.
(E) Alpha-ketoglutarate dehydrogenase enzymatic activity assay conducted on tumors shown in (D).
(F) OGDH knockdown affects steady-state pool size of multiple metabolites in vivo.
(A, B, E, and F) Error bars represent the SD from a representative experiment. *p < 0.01, #p < 0.05 (Student’s t test; n = 3).
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translation (Breslin and O’Driscoll, 2013). To further characterize
these stable cell lines in assays of increasing stringency, we uti-
lized a modified soft agar assay format, m3D (Figure 3A). Given
that multiple agents have shown diminished potency in the
context of 3D cultures, we intended to introduce the OGDH
knockdown only in the setting of already established colonies.
First, we plated the cells without doxycycline, thus keeping the
shRNA expression off, and allowed the colonies to form to
roughly 100- to 120-mm size. At that time, doxycycline was
added, and the cells were further incubated in the presence of
doxycycline until the colonies in the control plates were clearly
visible to the naked eye (500–700 mm). While the classic method
of scoring the effects on growth relies on comparing the experi-
mental arms with doxycycline to those without doxycycline, we
focused on comparing the size of the preformed colonies at
the start of the assay to the colonies with doxycycline at the
end of the assay. Strong hits were defined as cell lines that did
not show any evidence of further growth after doxycycline
addition.
We constructed three stable lines (shNT, sh815, sh885) in
each of the 59 cell lines and observed a broad range of the sen-
sitivities in multiple assays (Figures 3B and 3C). Because not all
the cell lines were capable of forming colonies in soft agar, the
direct comparison of 2D versus m3D effects was possible only
in 38 cell lines. Interestingly, although most of the cell lines
were sensitive to OGDH knockdown in a 2D assay, and thus
termed OGDH-dependent, significantly fewer lines displayed
OGDH dependence in the context of the m3D assay. In fact,
when using the most stringent criteria of looking for absolute
growth after doxycycline addition to preformed colonies, only
four cell lines were scored as OGDH dependent. Representative
images of multiple cell lines within each category are shown in
Figure 3B. Importantly, a similar extent of OGDH knockdown
was observed in the vast majority of cell lines (Figure 3D; data
not shown), as well as in both 2D and m3D assay formats
(Figure S3A). Interestingly, some cell lines appear to display
higher levels of OGDH expression in the context of soft agar col-
onies (Figure S3B), but this observation does not appear to
correlate with sensitivity to OGDH knockdown.
To further show that differential effects on cell growth were
due to inherent sensitivities rather than to differential extent of
OGDH inhibition, we conducted 13C5-glutamine labeling experi-
ments in several representative cell lines. Consistent with com-
parable OGDH depletion in these cell lines, the TCA cycle inter-
mediates were similarly affected showing significant decreases
in 13C4-malate, aspartate, and citrate isotopomers. While some
cell lines displayed effects on 13C5-glutamate isotopomer levels,
those were not correlated with sensitivity to OGDH knockdown
(Figure 3E). Collectively, these data suggest that, while OGDH
activity is comparably inhibited in OGDH-dependent and -inde-
pendent cell lines, the cellular response can be dramatically
different.
To functionally characterize the cellular consequence of
OGDH knockdown in OGDH-dependent cells, we have conduct-
ed a time-course experiment analyzing growth of 22RV1 and
H508 cells lines (Figure S3C). OGDH knockdown resulted in pro-
found growth defects and cell-cycle abnormalities, such as a
decrease in S phase population and a concurrent expansion of880 Cell Reports 17, 876–890, October 11, 2016the subG1 population, suggesting that both cell death and
reduced proliferation contribute to the phenotype (Figure S3D).
Characterization of Putative alpha-Ketoglutarate
Dehydrogenase Inhibitors
Using the highly annotated set of OGDH-dependent and OGDH-
independent cell lines, we evaluated published putative small
molecule inhibitors of alpha-ketoglutarate dehydrogenase com-
plex, succinyl phosphonate (SP), andCPI-613 (Bunik et al., 2005;
Stuart et al., 2014). Using several different criteria, we showed
that these molecules cannot be used as specific OGDHC inhib-
itors in cell-based assays. First, dose titration of SP and CPI-613
showed similar sensitivity of representative OGDH-dependent
and OGDH-independent cell lines, A549 and H838, respectively
(Figure S4A). Second, metabolomics studies of A549 cells
treated with SP clearly showed no major impact on overall
pool levels of TCA cycle intermediates or labeling patterns using
13C5-glutamine tracer (Figure S4B). Treatment of A549 cells with
CPI-613 resulted in significant TCA cycle perturbations, as
judged by overall metabolite pool levels and 13C5-glutamine
tracer labeling patterns (Figure S4C), but thosewere inconsistent
with the shRNA studies shown in Figure 2. Third, we assessed
the effects of these compounds on OGDHC enzymatic activity
in A549 cell lysates. Although SP was able to inhibit OGDHC
lysate activity with IC50 of 3.9 mM, CPI-613 was able to do it
only at 248 mM (Figure S4D). Collectively, these results point to
some of the key limitations of these tool compounds (cell pene-
tration for SP and lack of specificity for CPI-613) and highlight the
insights that can be gained when using the highly validated
shRNA tools. In fact, CPI-613 has been previously described to
also inhibit pyruvate dehydrogenase (Zachar et al., 2011).
In Vivo Dependence on OGDH
To investigate the in vitro to in vivo translation of our findings, we
conducted multiple xenograft efficacy studies. One of the most
sensitive cell lines to OGDH knockdown in the stringent m3D
assay, 22RV1, showed a dramatic response in vivo (Figure 4A).
To further demonstrate the specificity of this response, we con-
ducted an expanded study with additional shRNAs and a wild-
type OGDH rescue arm of sh885 (Figure S5A). Similar efficacy
was observed with additional shRNAs and, as with the in vitro
studies, functional rescue of sh885 cell line was observed with
overexpression of wild-type OGDH (Figure S5B). Extending
these results, striking in vivo dependence on OGDH was also
demonstrated for H508 cells (Figure 4B). Additional cell lines
evaluated (HEC1A and HT1080) gave similar results to A549 cells
(data not shown) or showed no efficacy (U87MG) (Figure S5C).
Interestingly, when compiling all in vitro and in vivo results, it ap-
peared that the most pronounced in vivo responses tracked with
the stringent m3D assay in vitro (Figure 4C). As such, this work
highlights the importance of assessing growth in multiple for-
mats and presents a promising in vitro assay that closely tracks
with dramatic in vivo responses.
Aspartate Is an Alternative Anaplerotic Source for the
TCA Cycle
To elucidate factors affecting sensitivity to OGDH knockdown,
we decided to develop deeper understanding of metabolic
CA
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Figure 4. A Subset of Cancer Cell Lines Displays Profound OGDH
Dependence In Vivo
(A) Xenograft growth of 22RV1 cells engineered to harbor sh885 and shNT
constructs. Doxycycline was added to induce shRNA expression once tumors
were approximately 200 mm3. Error bars represent SEM.
(B) Xenograft growth of H508 cells engineered to harbor sh885 and shNT
constructs. Doxycycline was added to induce shRNA expression once tumors
were approximately 200 mm3. Error bars represent SEM.
(C) Correlation between different in vitro assay formats and the in vivo efficacy.
Percentage of tumor growth inhibition (TGI) and the associated p values are
shown from two independent replicate experiments, where available. NS, no
statistical significance.TCA cycle inputs and outputs. In particular, we focused on alter-
native anaplerotic TCA cycle sources in OGDH-independent
cells where such pathways are predicted to be active. We chose
H838 cells because they showed clear OGDH independence
and, using a CRISPR system, we derived KO clones for DLST,
a unique E2 subunit of alpha-ketoglutarate dehydrogenase com-
plex. Multiple individual clones showed a clear loss of DLST pro-
tein and one was chosen for further characterization (Figure 5A).Figure 3. Cancer Cells Display a Broad Range of Sensitivities to OGDH
(A) Schematic representation of the modified 3D soft agar assay used (m3D). 22
(B) Representative images of cells grown in 2D andm3D assays are shown to illust
the sh885 construct allowing inducible OGDH knockdown. Colored bars on the
legend can be found in (C).
(C) Summary of OGDH sensitivities in 2D and m3D assays observed across 59 c
(D) Immunoblot analysis showing similar levels of OGDH knockdown in cell lines of
allowing inducible OGDH knockdown. Expression was monitored after 4 days of
(E) TCA cycle is similarly affected by OGDH knockdown in cell lines of different OG
cell lines displayed harbor the sh885 construct allowing inducible OGDH knockdo
line control without dox treatment. Error bars represent the SD from a represent
882 Cell Reports 17, 876–890, October 11, 2016Consistent with the initial OGDH knockdown results, the DLST-
KO cells showed only a very mild proliferation defect phenotype
(Figure 5B). To demonstrate that the cells lacked an OGDHC ac-
tivity, we conducted a 13C5-glutamine labeling experiment and
showed that despite comparable levels of 13C5-glutamate and
13C5-aKG in both cell lines, no
13C4-fumarate,
13C4-malate, or
13C4-aspartate was formed (Figure 5C). Importantly, OGDH
knockdown resulted in qualitatively similar 13C5-glutamine label-
ing results of mostmetabolites consistent with only partial loss of
OGDHC function (Figure S6A). Interestingly, we observed a dif-
ference in 13C5-aKG pattern in the context of DLST-KO cells
versus OGDH knockdown that might reflect differences in
chronic versus acute loss of OGDHC function, respectively (Fig-
ures 5C and S6A). Therefore, the above results suggest that
DLST-KO cells represent a useful tool of cells with a complete
break in the oxidative TCA cycle, while confirming that DLST is
a non-redundant member of the OGDHC complex.
The DLST-KO cells provided a unique opportunity to investi-
gate additional anaplerotic carbon sources that may be used
byOGDH-independent cells in the event of TCA cycle disruption.
As such, uniformly 13C-labeled glucose, glutamine, aspartate,
tyrosine, arginine, lysine, isoleucine, leucine, and valine were
individually supplied for 4 hr to H838 wild-type and DLST-KO
cells, and labeling patterns were assessed based on predicted
carbon flow pathways (Figure 5D). DLST-KO cells showed a
greater percentage of 13C3-malate derived from
13C6-glucose,
suggestive of a differential pyruvate carboxylase involvement
(Figure S6B). However, the absolute abundance of 13C3-malate
was not changed in these cells, and the signal was thus primarily
driven by decreased overall malate pool levels in DLST-KO cells.
Differential pyruvate dehydrogenase involvement was also sug-
gested by the dramatic decrease in 13C2-citrate levels (Fig-
ure S6C). Interestingly, total pools of citrate remained the same
in both cell lines, suggesting an alternative anaplerotic source
being used. No difference between the two cell lines and very lit-
tle net flow of carbon to the TCA cycle were observed with
leucine, isoleucine, valine, tyrosine, and lysine. In contrast, there
was substantial contribution from 13C4-asparate to TCA cycle
carbon pools as shown for malate, and the fractional contribu-
tion from aspartate was increased by 2.5-fold upon DLST
knockout (Figure 5E). While the total levels of malate were some-
what reduced in DLST-KO cells, the 13C4-malate abundance
actually increased, suggesting more aspartate-derived carbon
was converted to malate.
To further elucidate the mechanisms by which aspartate con-
tributes to TCAcycle,we used 15N,13C4-aspartate labeling exper-
iments. Specifically, we examined three possible aspartateKnockdown
RV1 cells with OGDH knockdown (sh885) are shown as an example.
rate differential sensitivities to OGDH knockdown. All cell lines displayed harbor
bottom of the panel denote clustering of cells based on m3D results. Detailed
ancer cell lines.
different OGDH sensitivities. All cell lines displayed harbor the sh885 construct
dox treatment.
DH sensitivities as demonstrated by a 13C5-glutamine labeling experiment. All
wn. Results are plotted as percentage of change as compared to the same cell
ative experiment. *p < 0.01, #p < 0.05 (Student’s t test; n = 3).
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Figure 5. Aspartate Is an Alternative Anaplerotic Source for the TCA Cycle
(A) Immunoblot analysis showing no DLST expression in the DLST-KO cells in comparison to H838 wild-type cells.
(B) Relative growth rates of wild-type H838 and DLST-KO cells.
(C) DLST-KO cells display no OGDHC activity, as determined by 13C5-glutamine-labeling patterns.
(D) Schematic illustration of the labeling experiment showing potential anaplerotic sources of carbon into the TCA cycle.
(E) Analysis of malate illustrates differential handling of 13C4-aspartate in DLST-KO cells as compared to the H838 wild-type cells. Total malate pool size,
13C4-malate, and percentage of
13C4-malate isotopomer abundance are shown.
(F) Diagnostic 15N transfer onto glutamate in the 15N,13C4-aspartate labeling experiment, indicating significant malate-aspartate shuttle activity in H838 wild-type
cells.
(G) DLST-KO cells display higher level ofmalate-aspartate shuttle activity than H838wild-type cells, asmeasurement by percentage of 15N-glutamate isotopomer
abundance after 15N,13C4-aspartate labeling.
(B–G) Error bars represent the SD from a representative experiment. *p < 0.01, #p < 0.05 (Student’s t test; n = 3).pathways, eachpotentially generating 13C4-fumarate or
13C4-ma-
late, and followed the 15N transfer as a diagnostic marker of
the specific pathway utilized (urea cycle usage generating
15N,13C4-argininosuccinate and ultimately
15N-arginine; malate-
aspartate shuttle usage generating 15N-glutamate; purine biosyn-
thetic pathway usage generating 15N-AICAR and 15N-IMP) (Fig-
ures S6D–S6F). We observed clear evidence of malate-aspartateshuttle activity and no evidence of the other two pathways being
involved in parental H838 cells (Figure 5F). To directly compare
the malate-aspartate shuttle activity in DLST wild-type and
DLST-KO cells, we used 15N,13C4-aspartate labeling experi-
ments. DLST-KO cells displayed significantly higher levels of
15N-glutamate isotopomer as compared to DLST wild-type cells
(Figure 5G), consistent with the initial result observed in carbonCell Reports 17, 876–890, October 11, 2016 883
tracing studies (Figure 5E). Collectively, these results highlight the
cellular flexibility in usinganaplerotic sourcesandsuggest that the
ability to utilize aspartatemight represent a compensatorymech-
anism in situations where TCA cycle is interrupted, in this case at
the alpha-ketoglutarate dehydrogenase step.
Differential Aspartate Utilization by OGDH-Dependent
and OGDH-Independent Cell Lines
To further investigate the differential utilization of aspartate, we
screened a number of cell lines with 15N,13C4-aspartate and
monitored the incorporation of 15N-label into 15N,13C4-arginino-
succinate, 15N-IMP, and 15N-glutamate. Consistent with our
initial results, we observed a correlation between cell lines that
displayed pronounced OGDH dependence in the m3D assay
and the decreased levels of the malate-aspartate shuttle activity
(Figure 6A). This correlation was further confirmed by investi-
gating the fate of carbon derived from aspartate by specifically
monitoring 13C4-citrate isotopomer levels (Figure 6B). The differ-
ences between cell lines were not accounted for by differential
ability to take up the 15N,13C4-aspartate from the media (Fig-
ure 6C). Similarly to the results observed in H838 cells, we did
not observe any 15N-label incorporation into 15N,13C4-arginino-
succinate and 15N-IMP (data not shown). Importantly, the cells
that were dependent on OGDH in 2D, but became less depen-
dent on OGDH in the m3D assays, still displayed a significant
level of 15N-glutamate and 13C4-citrate signal and hence tracked
with the OGDH-independent group. This observation is note-
worthy as it suggests the feasibility of an expanded nutrient
utilization screen to identify additional OGDH-dependent cell
lines, a preferable option over the labor-intensive shRNA-based
approach.
To specifically test the contribution of aspartate to the OGDH
phenotypes observed, we conducted a series of experiments
involving alterations of media composition. As predicted, sup-
plementation of media with high levels of aspartate was able to
rescue growth defects conferred by OGDH knockdown in multi-
ple cell lines that were sensitive to OGDH knockdown in 2D and
that maintained some basal level of malate-aspartate shuttle ac-
tivity (Figure 6D; data not shown). Interestingly, some minimal
threshold of malate-aspartate shuttle activity might be required,
as aspartate rescue did not effectively rescue OGDH-mediated
growth defects in H508 cells (data not shown). Conversely, we
showed that OGDH-independent cells, such DLST-KO, are
exquisitely sensitive to media aspartate levels, as they displayed
a profound growth defect in the context of aspartate dropout
media (Figure 6E).
To demonstrate that this role of aspartate requires functional
malate-aspartate shuttle, we knocked down its critical compo-
nents—glutamic-oxaloacetic transaminases, GOT1 and GOT2.
In the context of media containing aspartate, we observed spe-
cific growth defects only in DLST-KO cells upon GOT2 knock-
down (Figure 6F). Since the levels of GOT1 and GOT2 knock-
down were roughly equivalent in both cell lines (Figure 6G), we
undertook a metabolomics approach to dissect the differences
between GOT1 and GOT2.We observed the expected increases
in overall aspartate total pool levels upon GOT1 knockdown and
decreases upon GOT2 knockdown (Figure 6H), consistent with
the previously observed aspartate-consuming role of GOT1884 Cell Reports 17, 876–890, October 11, 2016and aspartate-producing role of GOT2 (Son et al., 2013). Next,
we conducted 15N,13C4-aspartate labeling experiments to
monitor the levels of 15N-label transfer onto glutamate and
observed modest effects upon GOT2 knockdown (Figure 6I).
Since the interpretation of these results is complicated by the
fact that the assay does not distinguish between the individual
aminotransferases, we employed an alternative 13C5-glutamine
labeling strategy to monitor 13C4-aspartate levels. Similarly
to total aspartate pool levels, GOT1 knockdown increased
13C4-aspartate isotopomer abundance, and GOT2 knockdown
decreased 13C4-aspartate isotopomer abundance (Figure 6J).
Interestingly, the lowest levels of aspartate were observed
in DLST-KO cells upon GOT2 knockdown, thus correlating
with growth defects observed (Figure 6F). Collectively, these
data support the critical role of aspartate, and the malate-
aspartate shuttle, in mediating cellular response to OGDH
knockdown.
Differential Effects of OGDH Knockdown on Cellular
Respiration
To functionally demonstrate the aspartate contribution to respi-
ration, we directly measured the mitochondrial oxygen con-
sumption rate (OCR) of several OGDH-dependent and -indepen-
dent cell lines. Importantly, the measurements were done in
RPMI media containing much higher concentrations of glucose
and glutamine as compared to aspartate (11 mM, 2 mM,
150 mM, respectively). Several observations highlight the funda-
mental differences between OGDH-dependent and -indepen-
dent cell lines. First, we observed a significantly higher basal
respiration rate in OGDH-dependent cell lines (22RV1 and
H508) as compared to the OGDH-independent ones (HCT15,
DLD1, and H838) (Figure 7A). Second, the OGDH-dependent
cell lines tended to have a larger decrease in basal OCR upon
OGDH knockdown. This relative impact of OGDH knockdown
was also observed in OGDH-dependent cell lines with more in-
termediate levels basal OCR (A549 and AGS), further supporting
their particular reliance on OGDHC activity.
To further understand the respiration in these cells we used
FCCP, a well-established uncoupling agent that collapses the
proton gradient. The result of mitochondrial membrane potential
disruption is uninhibited electron flow through the electron trans-
port chain (ETC) and maximal oxygen consumption by complex
IV. The difference between basal respiration and FCCP-stimu-
lated respiration can be used to assess reserve respiratory ca-
pacity, a measure of cellular ability to respond to increased en-
ergy demand. Interestingly, we observed a larger response to
FCCP in OGDH-dependent cell lines, and, most importantly,
OGDH knockdown almost completely abrogated this response
(Figure 7B). The OGDH-independent cell lines displayed signifi-
cant residual reserve respiratory capacity after OGDH knock-
down, consistent with additional mechanisms maintaining the
TCA cycle and ETC activities. To evaluate the relative contribu-
tion of the malate-aspartate shuttle to this activity, we used a
previously described aminotransferase inhibitor aminooxyace-
tate, AOA (Son et al., 2013). As predicted, we observed a signif-
icant reduction of FCCP-stimulated OCR by AOA in OGDH-inde-
pendent cells (DLD1 and HCT15), as assessed in cells with
OGDH knockdown (Figure 7C). Interestingly, even at the highest
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Figure 6. Differential Aspartate Utilization in OGDH-Dependent and OGDH-Independent Cell Lines
(A) Aspartate utilization in vitro correlates with OGDH sensitivity in vivo. 15N,13C4-aspartate labeling was used to assess the malate-aspartate shuttle activity by
following the diagnostic 15N-transfer to glutamate.
(B) Alternative readout of malate-aspartate shuttle activity confirming carbon labeling of the TCA cycle intermediates. 15N,13C4-aspartate labeling was used to
show the appearance of 13C4-citrate.
(C) Percentage of 15N,13C4-aspartate uptake across multiple cell lines.
(D) Aspartate can rescue growth defects induced by OGDH knockdown. OGDH-dependent cell lines were plated in 2D colony formation assay in regular RPMI
media and supplemented with additional aspartate.
(E) DLST-KO cells are particularly sensitive to media aspartate levels. OGDH-independent cells, H838 wild-type (WT) and H838 DLST-KO, were plated in 2D
colony formation assays in a dropout media specifically testing the role of aspartate.
(legend continued on next page)
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AOA concentrations tested we observed no effects on basal
respiration rates in any of the cell lines tested (data not shown).
These significant differences in how OGDH-dependent and
OGDH-independent cells respire, prompted us to conduct
several additional controls. First, wemeasured overall ATP levels
and showed no differences between OGDH-dependent and
OGDH-independent cell lines upon OGDH knockdown (Fig-
ure S7A). Second, we measured ROS levels using CM-
H2DCFDA dye and showed significantly higher basal ROS levels
in OGDH-dependent cells compared to OGDH-independent
cells, perhaps consistent with the differential oxygen consump-
tion rates observed. Interestingly, we observed no significant dif-
ferences in ROS levels upon OGDH knockdown (Figure S7B).
Similarly, we investigated mitochondrial superoxide levels using
MitoSOX dye and observed no significant differences upon
OGDH knockdown (Figure S7C). Third, we measured NAD+/
NADH ratio and found that OGDH knockdown resulted in prefer-
ential decrease of NAD+/NADH ratio in OGDH-dependent cells
(Figure S7D). Since the OGDHC reaction generates mitochon-
drial NADH, this result was unexpected and is likely to be an in-
direct reflection of the overall cellular energetic state of OGDH-
dependent cells responding to target knockdown rather than a
direct readout of alpha-ketoglutarate dehydrogenase reaction.
Collectively, the above results support the specificity of the
observed effects on cellular respiration and are consistent with
amodel where OGDH-independent cells can use multiple mech-
anisms to maintain respiration, including the malate-aspartate
shuttle, while the OGDH-dependent cell lines lack this metabolic
flexibility (Figure 7D).DISCUSSION
Alpha-ketoglutarate dehydrogenase complex is composed of
three well-described subunits: E1 encoded by OGDH, E2 en-
coded by DLST, and E3 encoded by DLD. An additional subunit
of the OGDH complex, Kgd4, was recently identified in yeast and
shown to be necessary for stable complex formation (Heublein
et al., 2014). While mechanisms regulating the biochemical reac-
tion catalyzed by OGDHC are beginning to emerge (Armstrong
et al., 2014; Bunik and Fernie, 2009), the cellular and organismal
roles of OGDHC remain relatively poorly defined. Profound loss
of OGDHC function appears to be deleterious, as evidenced
by embryonic lethality of Dlst KO mice (Yang et al., 2009), Dld
KOmice (Johnson et al., 1997), and aKG aciduria found in human
patients with severely decreased levels of alpha-ketoglutarate
dehydrogenase activity (Dunckelmann et al., 2000).(F) DLST-KO cells display specific sensitivity to GOT2 knockdown in comparis
representative experiment.
(G) GOT1 and GOT2 knockdown levels were tested by qPCR in H838WT and H83
representative experiment.
(H) GOT1 and GOT2 knockdown effects on total aspartate pool levels.
(I) Aspartate aminotransferase activity, as measured by percentage of 15N-glutam
(J) GOT1 and GOT2 knockdown effects on 13C4-aspartate relative isotopomer
values are plotted on a log scale to allow comparison across a wide concentrati
(A–C) Cell lines are color-coded according to their phenotype in m3D assay, furthe
wells from a representative experiment. Student’s t test was performed, as indic
(H–J) Error bars represent the SD from a representative experiment. *p < 0.01, #
886 Cell Reports 17, 876–890, October 11, 2016Given the central role of the alpha-ketoglutarate dehydroge-
nase complex, it was surprising to uncover a subset of cell lines
that could maintain growth in the setting of near complete OGDH
knockdown. A greater range of cellular sensitivities to OGDH
knockdown was observed in the in vitro m3D setting, where in
fact only a small minority of cell lines displayed dramatic depen-
dence on OGDH. Notably, the m3D growth data closely tracked
with in vivo dependence on OGDH, highlighting that metabolic
wiring is highly context dependent. This point was recently illus-
trated by several studies demonstrating alterations in the
expression ofmetabolic genes (includingOGDH) and drug sensi-
tivity from the 2D to 3D cell culture setting (Mandujano-Tinoco
et al., 2013; Vinci et al., 2012). The metabolic flexibility of tumor
cells is exemplified by the DLST knockout experiment, in which
cells were capable of proliferation despite a complete break in
the TCA cycle, further supporting an emerging notion that the
these reactions are not a simple unidirectional cycle. Other ex-
amples include conditions where HIF-1a is stabilized (Metallo
et al., 2012;Wise et al., 2011) or themitochondrial electron trans-
port system is defective (Mullen et al., 2011), in which conversion
of aKG to isocitrate via reductive carboxylation is particularly
prominent as compared to the oxidative TCA cycle direction.
The hypoxia-induced switch in carbon flow is in part controlled
by HIF-1 controlled ubiquitin-mediated degradation of an
OGDH splice variant (Sun and Denko, 2014), shunting carbon
into citrate for lipid synthesis. Surprisingly, OGDH activity was
also demonstrated to help drive reductive carboxylation by
providing NADH as a substrate for nicotinamide nucleotide
transhydrogenase (NNT)-dependent NADPH formation (Mullen
et al., 2014).
This report adds another dimension to our understanding of
metabolic flexibility by highlighting differential utilization of the
malate-aspartate shuttle, a system thought primarily to shuttle
reducing equivalents from the cytosol into themitochondria (Fig-
ure S6F). Inactive or low malate-aspartate shuttle activity could
deprive the mitochondria of the cytosol-derived NADH sources,
such as glycolysis. In turn, these cells could be particularly
dependent on mitochondrial sources of NADH. The ability to
deliver aspartate carbon into the mitochondria also provides
cells with a potential anaplerotic source in the setting of disrup-
ted TCA cycle carbon flow. While the mechanistic link between
low malate-aspartate shuttle activity and dependence on
OGDH remains to be fully elucidated, our data are consistent
with a model wherein aspartate plays a dual role of providing
NADH to the mitochondria and carbon equivalents to the TCA
cycle. Further dissection of malate-aspartate shuttle involve-
ment will require future development of label tracing methodson to H838 WT cells. Error bars represent the SD of triplicate wells from a
8 DLST-KO cells. Error bars represent the SD of triplicate measurement from a
ate isotopomer abundance after 15N,13C4-aspartate labeling.
levels in 13C5-glutamine labeling experiment. The
13C4-aspartate isotopomer
on range.
r described in the legend of Figure 3C. Error bars represent the SD of triplicate
ated by the brackets.
p < 0.05 (Student’s t test; n = 3).
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Figure 7. OGDH Knockdown Differentially Affects Respiration of OGDH-Dependent and OGDH-Independent Cell Lines
(A) Basal oxygen consumption rates in multiple cell lines harboring sh885, as a function of OGDH knockdown. Percentages displayed indicate cell line-specific
decreases in respiration after OGDH knockdown. Cell lines are color-coded according to their phenotype in m3D assay, further described in the legend of
Figure 3C, and their OGDH dependence in 2D assays is denoted by the bracket above the panel.
(B) FCCP-stimulated oxygen consumption rates in multiple cell lines harboring sh885, as a function of OGDH knockdown. FCCP-stimulated OCR was calculated
based on the OCR difference before and after FCCP injection. Percentages displayed indicate cell-line-specific decreases in respiration after OGDH knockdown.
Cell lines are color-coded according to their phenotype in m3D assay, further described in the legend of Figure 3C, and their OGDH dependence in 2D assays is
denoted by the bracket above the panel.
(legend continued on next page)
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to specifically track cytosolic and mitochondrial aspartate
aminotransferase (GOT1 versus GOT2) and malate dehydroge-
nase (MDH1 versus MDH2) reactions. This is of particular inter-
est, as some reports have suggested the possibility of reverse re-
action direction, as driven by relative concentrations of individual
intermediates and mitochondrial membrane potential in specific
cellular contexts (Birsoy et al., 2015; Bremer and Davis, 1975).
Identifying the mechanisms that control malate-aspartate
shuttle activity will be of high interest, as such findings may
lead to the development of clinically tractable markers for iden-
tifying tumors with this particular metabolic vulnerability. Recent
studies have just begun to reveal such potential modes of ma-
late-aspartate shuttle regulation by identifying a stimulatory
role of GOT2 acetylation by SIRT3 (Yang et al., 2015). This future
direction will be of particular importance, as no genetic lesion in
cell lines analyzed was clearly associated with response to
OGDH knockdown in m3D or in vivo (data not shown). Our initial
proof-of-concept observation that OGDH dependence can be
modulated by knockdown of malate-aspartate shuttle compo-
nents, particularly GOT2 (Figure 6F), suggests that tumors with
low or absent GOT2 activity might be particularly sensitive to
OGDH inhibition. Further in vivo studies will be needed to vali-
date these hypotheses.
Recent reports have highlighted the essential role of the ETC in
maintaining aspartate biosynthesis in proliferating cells (Birsoy
et al., 2015; Sullivan et al., 2015). Our results build upon these
studies by demonstrating, in a broader panel of cancer cell lines,
that not only is a functional TCA cycle key for generating aspar-
tate, but that a differential ability to utilize aspartate can dictate
the ability of cells to survive and grow in the setting of a disrupted
TCA cycle. Furthermore, the metabolite tracing experiments and
oxygen consumption rate measurements suggest that the role of
aspartate extends beyond the direct support of cellular biosyn-
thetic needs to more broadly affecting mitochondrial function
(Birsoy et al., 2015; Sullivan et al., 2015). Interestingly, our results
are consistent with the concept of an aspartate threshold neces-
sary for cellular viability (Birsoy et al., 2015), as the DLST-KO
cells upon GOT2 knockdown displayed the lowest levels of
aspartate and were the only ones to display growth defects.
The circulating levels of aspartate are some of the lowest among
all the circulating amino acids (Mayers and Vander Heiden,
2015); thus, the ability to take up and utilize aspartate as an ana-
plerotic backup mechanism remains to be further tested. Devel-
opment of specific small molecule inhibitors targeting OGDH
and themalate-aspartate shuttle components will enable deeper
in vitro and in vivo analyses of these metabolic pathways.
Collectively, our findings highlight OGDH as a potential thera-
peutic target in a metabolically distinct subset of cancers. The
analysis of this group of cell lines revealed another mechanism
underlying the general robustness and redundancy of meta-
bolism through a role of themalate-aspartate shuttle, particularly(C) Malate-aspartate shuttle contribution to FCCP-stimulated oxygen consumptio
calculated based on the OCR difference before and after FCCP injection.
(D) Schematic illustrating the functional connection of malate-aspartate shuttle (M
profound consequences on the ability of cells to proliferate in the conditions of T
display low levels of MAS, while OGDH-independent cell lines display higher lev
(A–C) Error bars represent the SD of six wells from a representative experiment.
888 Cell Reports 17, 876–890, October 11, 2016under conditions of TCA cycle disruption. More broadly, our find-
ings linking OGDH dependence to differential aspartate usage
suggest a wider utility of nutrient utilization screens to identify
phenotypically distinct cancer subsets and to identify additional
metabolic nodes for targeted cancer therapy.
EXPERIMENTAL PROCEDURES
Cell Lines
All cell lines described in these studies were obtained from the American Type
Culture Collection (ATCC), Japanese Collection of Research Bioresources
(JCRB) Cell Bank, or Sigma. Cells were routinely cultured in their preferred me-
dia according to vendor recommendations. Cells harboring inducible shRNA
constructs were maintained in appropriate media with tetracycline-free fetal
bovine serum (631101, Clontech Laboratories).
Xenograft Studies
Experiments were carried out under an Institutional Animal Care and Use
Committee-approved protocol, and institutional guidelines for the proper
and humane use of animals were followed. See the Supplemental Experi-
mental Procedures for additional details.
siRNA Transfections
The general scheme of the transfection protocol of A549 cells is illustrated in
Figure S1A. 2e5 cells were plated in 6-cm dishes to achieve 40% confluence
at the time of transfection. Cells were transfected with ON-TARGETplus
SMARTpool siRNAs (Dharmacon) using Lipofectamine RNAiMAX (13778-
150, Life Technologies) for 4 hr at 10 nM in OPTI-MEM media (31985-070,
Life Technologies). Subsequently, equal volume of cell media was added con-
taining 20% FBS, to achieve 5 nM siRNA and 10% FBS final concentrations,
and the transfection was allowed to go on overnight. Next day, media was
exchanged over cells for fresh 10% FBS containing media. The following
day, the transfection protocol was repeated again. 24 hr after the second
transfection, cells were trypsinized, counted, and plated for 96-well-format
growth assays.
Matching control siRNA, NT, was purchased from Dharmacon (D-001810-
10-05).
The protocol for siRNA transfection of H838 cells was the same as for A549
cells. GOT1 was knocked down using ON-TARGETplus siRNA (J-011673-10,
GE Dharmacon). GOT2 was knocked down using ON-TARGETplus siRNA
(J-011674-10, Dharmacon).
Lentiviral Techniques
Lentivirus-based (shRNAs or cDNA overexpression) constructs were made
using the standard protocol from The RNAi Consortium (TRC) protocol from
the Broad Institute (http://portals.broadinstitute.org/gpp/public/resources/
protocols). shRNA viruses were titered on individual target cell lines and in-
fected at MOI no greater than 0.7. cDNA overexpression viruses were infected
at higher MOI, where possible. To infect, cells were centrifuged for 1 hr at
2,250 rpm in the presence of the viruses and 8 mg/ml polybrene (H9268,
Sigma). Media was preplaced after the spin, and drug selection was added
24 hr later (puromycin or neomycin, as appropriate). Selection was carried
out until uninfected control cells were all dead. See the Supplemental Experi-
mental Procedures for shRNA sequences and additional details.
13C5-glutamine and
15N,13C4-aspartate Labeling Studies
shRNA-containing cells were pre-treated for 3 days with 200 ng/mL doxycy-
cline to induce target gene knockdown. Subsequently, cells were plated atn rates was assessed using AOA tool compound. FCCP-stimulated OCR was
AS) and the tricarboxylic acid (TCA) cycle. The differential activity of MAS has
CA cycle disruption, such as OGDH knockdown. OGDH-dependent cell lines
els of MAS activity.
*p < 0.01, #p < 0.05 (Student’s t test).
60%–70% confluency in triplicate in fresh media containing the same concen-
tration of doxycycline and incubated overnight. Water was used as the ‘‘-dox’’
control in all the experiments. The next day, media was replaced with a media
containing 2 mM 13C5-glutamine. Labeling was done for 3 hr after which the
cells were washed three times with 1 3 PBS (pH 7.4), and metabolites were
extracted by the addition of ice cold 80% methanol. Cell debris was removed
by centrifugation and samples were dried under a stream of nitrogen air.
Internal standard (L-Glutamic acid-13C5-
15N-d5, 749850, Sigma-Aldrich) at
1 mg/mL was added during the extraction step.
15N,13C4-aspartate labeling studies were done similarly except a 4 hr incu-
bation period was used.
In all labeling studies, the reported amounts of labeled species have been
corrected for natural isotope abundance. See the Supplemental Experimental
Procedures for detailed description of sample processing, LC-MS, and data
analysis.
Statistical Analysis
Analyses were performed using GraphPad software package. All data are ex-
pressed as mean of multiple measurements (n, indicating the number of repli-
cates). Error bars represent SEM for all in vivo studies and SD for all the in vitro
studies. Student’s t test was used to assess statistical significance. Exact
values and cutoff are specified within each figure or figure legend.
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